Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q14012
UPID:
KCC1A_HUMAN
Alternative names:
CaM kinase I; CaM kinase I alpha
Alternative UPACC:
Q14012; Q3KPF6
Background:
Calcium/calmodulin-dependent protein kinase type 1 (CaM kinase I), also known as CaM kinase I alpha, plays a pivotal role in the calcium-triggered CaMKK-CaMK1 signaling cascade. It regulates various cellular processes, including transcription activator activity, cell cycle progression, hormone production, and cell differentiation. This kinase is crucial for neurite outgrowth, axonal extension, and the formation of spines and synapses in hippocampal neurons, facilitating long-term potentiation and neuronal differentiation.
Therapeutic significance:
Understanding the role of Calcium/calmodulin-dependent protein kinase type 1 could open doors to potential therapeutic strategies.